|||as a primary anaesthetic agent for the induction and maintenance of anaesthesia with 100% oxygen in patients undergoing cardiac surgery associated with the use of cardiopulmonary bypass apparatus;|
|||as an analgesic adjunct in the maintenance of balanced general anaesthesia in cardiac surgery associated with the use of cardiopulmonary bypass apparatus, as well as surgical procedures requiring endotracheal intubation and ventilation.|
|||the postoperative management of pain following general surgery, thoracic or orthopaedic procedures and Caesarean sections, as an analgesic adjunct to epidural bupivacaine with or without adrenaline during labour and vaginal deliveries.|
|Proper placement of a needle or catheter in the epidural space should be verified before SUFENTA FORTE is injected to assure that unintentional intravascular or intrathecal administration does not occur. Unintentional intravascular injection of SUFENTA FORTE could result in potentially serious overdose including acute truncal muscular rigidity and apnoea. Unintentional intrathecal injection of the full sufentanil, bupivacaine epidural doses and volume could produce effects of high spinal anaesthesia including prolonged paralysis and delayed recovery. If analgesia is inadequate, the placement and integrity of the catheter should be verified prior to administration of any additional epidural medications. SUFENTA FORTE should be administered by slow injection.|
|With epidural administration, caution should be exercised in the presence of respiratory depression and in the presence of foetal distress.|
Epidural administration requires that the patient should be in a high care environment with continuous supervision.
The patient should be closely monitored for at least 2 hours after each dose, as early respiratory depression may occur.